---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-066233"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:57:46.993293+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q2 2023 net loss $16.1M; cash $115.8M; first patient dosed in LR-MDS trial

## Summary
- Net loss of $16.1M for Q2 2023 vs $10.4M in Q2 2022; R&D expenses increased to $13.3M from $8.1M.
- Cash and cash equivalents $115.8M as of June 30, 2023, up from $38.3M at Dec 31, 2022; runway through 2024.
- First patient dosed in Phase 1 trial of briquilimab for lower-risk MDS (LR-MDS) at Moffitt Cancer Center.
- Key appointments: Scott Brun to Board, Edwin Tucker as CMO, and others to Scientific Advisory Board and leadership.
- Company plans to initiate chronic spontaneous urticaria study in coming months.

## SEC filing metadata
- accession: 0001213900-23-066233
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/0001213900-23-066233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/ea183229-8k_jasperthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-066233
- JSON: https://secwatch.observer/filing/0001213900-23-066233.json
- Plain text: https://secwatch.observer/filing/0001213900-23-066233.txt

## Key facts
- Earnings Releases
  Jasper Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net Loss: For the quarter ended June 30, 2023, net loss was $16.1 million compared to net loss of $10.4 million for the.
  - Period: the quarter ended June 30, 2023
  - Net income: Net Loss: For the quarter ended June 30, 2023, net loss was $16.1 million compared to net loss of $10.4 million for the
  - Result: reported results
  source text: On August 11, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2023 and providing a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023066233/0001213900-23-066233-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.